Skip to main content

Table 4 Engineered MSCs for treatment reaching the clinical stage

From: Challenges and advances in clinical applications of mesenchymal stromal cells

Delivery system

Administration route

Sponsor

Indication

Development phase

Status

NCT number

MSCs secreting IFN-β

Intraperitoneal

M.D. Anderson Cancer Center, Dallas TX

Ovarian cancer

Phase 1

Active, not recruiting

NCT02530047

MV-NIS infected adipose tissue–derived MSCs

Intraperitoneal

Mayo Clinic, Rochester MN

Recurrent ovarian cancer

Phase 1/2

Recruiting

NCT02068794

Bone marrow-derived autologous MSCs infected with ICOVIR5, an oncolytic adenovirus (CELYVIR)

Intravenous

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Metastatic and refractory solid tumors

Phase 1/2

Completed

NCT01844661

MSCs genetically modified to express TRAIL

Intravenous

University College, London

Lung adenocarcinoma

Phase 1/2

Recruiting

NCT03298763

Autologous human MSCs genetically modified to express HSV-TK

Intravenous

Apceth GmbH & Co. KG, Germany

Advanced gastrointestinal cancer

Phase 1/2

Completed

2012–003,741-15 (EudraCT number)